Aimmune Therapeutics, Inc.
-
Ticker
AIMT
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 501-1000 Employees
- Based in Brisbane, California
Aimmune Therapeutics, Inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization
…More ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
REPORT RATINGS
4.8 / 5.0 (309)
Aimmune Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 309 reviews.
Aimmune Therapeutics, Inc.
Most Recent Annual Report
MOST RECENT
2019 Annual Report and Form 10K
Older/Archived Annual Reports